Details
Category: Volume 06 Issue 01 January 2018
Hits: 1600

Title: A Study to Evaluate the Role of Dihydrotestosterone in the Pathogenesis of Benign Hyperplasia of Prostate and Prostatic Carcinoma in Patients Attending a Tertiary Care Hospital in Eastern India

Authors: Atrayee Roy Choudhury, Sharmistha Chatterjee, Mousumi Mukhopadhyay, Biswajit Majumder

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i1.09

Abstract

Benign hyperplasia of prostate and prostatic carcinoma are two important diseases of aging male with very high incidence rate. Androgens have been implicated in the pathogenesis of both BHP and Ca prostate. Dihydrotestosterone (the 5-α reduced derivative of Testosterone) is the major metabolite of testosterone in prostate. So DHT is thought to play an important role in the development and progression of both the diseases. The present study was aimed at assessing the inter-relationship between the tissue level of 5α-dihydrotestosterone and pathogenesis of benign hyperplasia of prostate and prostatic carcinoma. The tissue level of DHT has been estimated in transition zone and peripheral zone of prostate in BHP and Ca prostate patients the comparative analysis of the above parameters suggests that, 5α-DHT is implicated in the pathogenesis of BHP and Ca prostate in a zone-wise manner. The findings of the present study also reveal that, prostatic tissue level of 5α-DHT may be explored as a possible marker for the diagnosis of benign hyperplasia of prostate and prostatic carcinoma.

Keywords: Benign hyperplasia of prostate, prostatic carcinoma, Dihydrotestosterone, transition zone, peripheral zone of prostate.

References

  1. Perls T, Terry D: Understanding the determinants of exceptional longevity. Ann Intern Med. 2003; 139:445
  2. Tinetti ME et al: Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004; 351:2870.
  3. Barry MJ, Roehrborn CG. Benign prostatic hyperplasia. BMJ. 2001; 323:1042.
  4. Ofner P, Harris RS, Wool IG, Loraine JA, and Thimann KV. Effects and metabolism of hormones. Academic Press, Inc., New York. 1968; 26: 237.
  5. Geller J. Benign prostatic hyperplasia: pathogenesis and medical therapy. Source: Department of Medical Education, Mercy Hospital and Medical Center, San Diego, CA 92103-2180. J Am Geriatr Soc. December 1991; 39(12):1208-16.
  6. Peter H. Gann, Charles H. Hennekens, Jing Ma, Christopher Longcope, Meir J. Stampfer. Prospective Study of Sex Hormone Levels and Risk of Prostate Cancer. Journal of the National Cancer Institute. August 21, 1996; Vol. 88,No. 16.
  7. Isom-Batz G, Bianco FJ Jr, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173:1935-1937.
  8. Kelly Chiles, MD, Stanton Honig, MD. Relationships of Testosterone and Prostate Cancer: A 2011 Perspective. May 01, 2011.
  9. Pierorazio PM, Ferrucci L, Kettermann A, et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010; 105:824-829.
  10. Nomura AM, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev. 1991; 13:200-27.
  11. Farnsworth, W. E., and J. R. Brown. E. P. Vollmer, editor. Testosterone metabolism in the prostate. In Biology of the Prostate and related tissues. National Cancer Institute Monograph. 1963; 12: 323.
  12. Farnsworth, W. E., and J. R. Brown. Metabolism of Testosterone by the human prostate. J. Amer. Med. Ass. 1963; 183: 436.
  13. Shimazaki, J., H. Kurihara, Y. Ito, and K. Shida. Testosterone metabolism in prostate; formation of androstan-17beta-ol-3-one and androst-4-ene, 17-dione, and inhibitory effect of natural and synthetic estrogens. Gunma J. Med. Sci. 1965;14: 313.
  14. Chamberlain, J., N. Jagarinec, and P. Ofner. Catabolism of [4-36C] testosterone by subcellular fractions of human prostate. Biochem. J. 1966; 99: 610.
  15. Gloyna, R. E., and J. D. Wilson. A comparative study of the conversion of testosterone to 17beta-hydroxy-5alpha-androstan-3-one (dihydro-testosterone) by prostate and epididymis. J. Clin. Endocrinol. Meatb. 1969; 29: 970.
  16. Siiteri Pentti K and Wilson Jean D. Dihydrotestosterone in prostatic hypertrophy: I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J. Clin Invest. September 1970; 49 (9): 1737-1745.
  17. Tsutomu Nishiyama, Toshihiko Ikarashi, Yutaka Hashimoto, Kazuya Suzuki and Kota Takahashi. Association Between the Dihydrotestosterone Level in theProstate and Prostate Cancer Aggressiveness Using the Gleason Score. The Journal of Urology.Vol. 176, 1387-1391, October 2006. DOI:10.1016/j.juro.2006.06.066.
  18. Qing Ji, Lilly Chang, Frank Z. Stanczyk, Murad Ookhtens,1 Andy Sherrod, and Andrew Stolz. Impaired dihydrotesto-sterone catabolism in human prostate cancer: a critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signalling. Pub Med. Cancer Res. 2007; 67: 1361–9.
  19. Bruce Montgomery, 1 Elahe A. Mostaghel, Robert Vessella, David L. Hess, Thomas F. Kalhorn, Celestia S. Higano, Lawrence D. True, and Peter S. Nelson. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Pub Med Central, Cancer research. 2008 June 1; 68(11): 4447–4454. doi: 10.1158/0008-5472.
  20. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Pub Med. Clinical Cancer Research.2004;10:440–8.
  21. Mark A. Titus, Michael J. Schell, Fred B. Lih, Kenneth B. Tomer and James L. Mohler. Testosterone and Dihydrotesto-sterone Tissue Levels in Recurrent Prostate Cancer. Clinical Cancer Research. July 1, 2005; 11: 4653. doi: 10.1158/1078-0432.
  22. Thorpe A, Neal D: Benign prostatic hyperplasia. Lancet. 2003; 366:1359.

Corresponding Author

Sharmistha Chatterjee

Assistant Professor, Department of Biochemistry,

College of Medicine and Sagore Dutta Hospital,Kamarhati, Kolkata

Ph No. 9830477927, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.